NEUROONE MEDICAL TECHNOLOGIES earnings release, August 13, 2026

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

NeuroOne® Reports

Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

$2.7 Million in Product

Orders Outpace Shipments of $2.0 Million

Company Has Received

Product Orders for Fiscal Year 2026 of $11.2 Million; Working with Suppliers to Maximize Product Shipments Through End of Fiscal Year

Received ISO 13485

Certification Ahead of Schedule; International Expansion Planned

StereoCED™ Drug

Delivery System Expected to be Available for Research and Investigational Clinical Studies by the End of Fiscal Year 2026

Management to Host

Conference Call at 8:30 a.m. Eastern Time Today

EDEN PRAIRIE, Minn., August 13, 2026

--

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and provided a business update for the third quarter of fiscal year 2026 ended June 30, 2026.

FY Q3 2026 Financial Highlights

Recent

Operational Highlights

Management

Commentary

“This quarter marked another period of revenue growth compared to 2025, with product revenue increasing 16% year-over-year to $2.0 million,” said Dave Rosa, CEO of NeuroOne. “Importantly, this growth is improving margins – product gross margins reached a record 59.9%, driven by a 29% increase in product gross profit to $1.2 million compared to the prior year period. Even more encouraging is that new product orders of $2.7 million during the quarter meaningfully outpaced revenue recognized during the quarter, growing our backlog to $1.7 million.

“Looking at the rest of the fiscal year, there’s a lot to be excited about: the launch of our StereoCED™ drug delivery platform for investigational and animal studies, continued growth of the OneRF® Brain Ablation System, onboarding independent distributor reps for the OneRF® Trigeminal Nerve Ablation System, selecting a partner for our basivertebral nerve ablation access tools, and planning for international expansion. In total, we continue to make meaningful progress with our technology platform across all verticals while adding to the patient success stories for those who are treated with our technology. This is our driving motivation.”

Summary of NeuroOne Therapies

OneRF®

Trigeminal Nerve Ablation System:

SteroeCED™

Drug Delivery Program:

Basivertebral

Nerve Ablation:

OneRF®

Ablation System in the Brain:

Third

Quarter Fiscal 2026 Financial Results

Product revenue increased to $2.0 million in the third quarter of fiscal 2026, a 16% increase compared to $1.7 million in the same year-ago quarter.

The increase was primarily driven by higher sales of OneRF®

Products.

Product gross profit increased 29% to $1.2 million, driving a product gross margin expansion to a record 59.9% in the third quarter of fiscal

2026, compared to $0.9 million, or 53.9%, in the same year-ago quarter. This 6.0 percentage point increase reflects a more favorable sales mix toward higher margin products.

Total operating expenses were $3.6 million in the third quarter of fiscal 2026, compared to $2.8 million in the same year-ago quarter. Selling,

General & Administrative expenses were $2.2 million, compared to $1.6 million as a result of increased headcount, sales and marketing costs, professional fees and other operating costs in the same year-ago quarter. Research & Development expenses were $1.4 million, compared to $1.2 million in the same year-ago quarter, reflecting the timing of product development activities.

Net loss in the third quarter of fiscal 2026 was $2.0 million, or ($0.23) per basic share and ($0.28) per diluted share, compared to net loss of $1.5 million, or ($0.19) per basic share and ($0.19) per diluted share, in the prior-year quarter.

As of June 30, 2026, cash and cash equivalents totaled $2.0 million, compared to $6.6 million as of September 30, 2025. Accounts receivable were $1.1 million as of June 30, 2026, compared to $1.3 million as of September 30, 2025, and inventory, net was $2.3 million as of June 30, 2026, compared to $2.2 million as of September 30, 2025. During the third quarter of fiscal 2026, the Company raised $0.4 million through its at-the-market offering program. Through June 30, 2026, the Company raised gross proceeds of $8.4 million under the at-the-market (“ATM”) program.

Subsequent to quarter-end, on July 13, 2026, the Company raised another $1.0 million through the issuance of 400,346 shares under the

ATM program representing the second time in calendar 2026 the ATM was utilized.

The

Company had working capital of $3.7 million as of June 30, 2026, compared to working capital of $7.9 million as of September 30, 2025.

The Company had no debt outstanding as of June 30, 2026.

All share and per share amounts in this release have been retroactively adjusted to reflect the one-for-six reverse stock split of the Company’s issued and outstanding common stock, which began trading on a split-adjusted basis on The Nasdaq Capital Market on April 16, 2026.

Conference

Call and Webcast

Management will host an investor conference call and webcast today, Thursday, August 13, 2026, at 8:30 a.m. Eastern time to discuss the Company’s fiscal third quarter 2026 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Date:

Thursday, August 13, 2026

Time:

8:30 a.m. Eastern time

U.S.

Dial-In (Toll Free):

888-506-0062

International

Dial-In:

973-528-0011

Participant

Access Code:

549778

Webcast:

NMTC FY Q3 2026 Earnings Call Webcast

Please join at least five minutes before the start of the call to ensure timely participation.

A... (truncathe call will be available through Thursday, August 27, 2026. To listen to the replay, please call 877-481-4010 within the

United States or 919-882-2331 when calling internationally, using replay passcode 54304. A webcast replay will also be available using the webcast link above through August 13, 2027.

About

NeuroOne

NeuroOne

Medical Technologies Corporation (NASDAQ: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation

System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, please visit nmtc1.com.

Forward

Looking Statements

Financial statements

Income Statement

For the Three Months Ended June 30, — (unaudited)

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Nine Months Ended June 30, – 2026For the Nine Months Ended June 30, – 2025
Product revenue1,973,1051,696,0506,727,7906,356,767
Cost of product revenue790,496781,2152,987,0892,743,982
Product gross profit1,182,609914,8353,740,7013,612,785
License revenue3,000,000
Operating expenses:Selling, general and administrative2,181,7681,618,9505,986,5945,602,818
Operating expenses:Research and development1,425,1531,182,4854,282,9233,865,376
Operating expenses:Total operating expenses3,606,9212,801,43510,269,5179,468,194
Operating expenses:Loss from operations-2,424,312-1,886,600-6,528,816-2,855,409
Operating expenses:Fair value change in warrant liability405,702319,625620,1711,099,421
Operating expenses:Financing costs-9,325-334,063
Operating expenses:Other income12,27975,43282,402103,898
Operating expenses:Loss before income taxes-2,006,331-1,500,868-5,826,243-1,986,153
Operating expenses:Net loss-2,006,331-1,500,868-5,826,243-1,986,153
Net loss per share (Note 3):Basic-0.23-0.19-0.68-0.32
Net loss per share (Note 3):Diluted-0.28-0.19-0.75-0.32
Number of shares used in per share calculations (Note 3):Basic8,661,6248,100,6038,511,3136,141,509
Number of shares used in per share calculations (Note 3):Diluted8,739,5058,100,6038,621,0756,141,509

Balance Sheet

Condensed Balance Sheets

As of – June 30, – 2026 – (Unaudited)As of – September 30, – 2025
Current assets:Cash and cash equivalents2,047,5966,570,382
Current assets:Accounts receivable1,098,9651,264,805
Current assets:Inventory, net2,290,2542,226,805
Current assets:Deferred offering costs33,04622,920
Current assets:Prepaid expenses318,940141,372
Current assets:Total current assets5,788,80110,226,284
Current assets:Intangible assets, net28,21044,946
Current assets:Right-of-use asset166,751255,195
Current assets:Property and equipment, net202,333259,222
Current assets:Total assets6,186,09510,785,647
Current liabilities:Accounts payable905,7161,010,369
Current liabilities:Accrued expenses and other liabilities1,135,7111,292,714
Current liabilities:Total current liabilities2,041,4272,303,083
Current liabilities:Warrant liability303,8051,266,894
Current liabilities:Operating lease liability, long term73,320143,148
Current liabilities:Total liabilities2,418,5523,713,125
Stockholders’ equity:Common stock, $0.001 par value; 100,000,000 shares authorized; 8,702,982 and 8,334,336 shares issued and outstanding as of June 30, 2026 and September 30, 2025, respectively.8,7038,334
Stockholders’ equity:Additional paid–in capital88,194,87085,673,975
Stockholders’ equity:Accumulated deficit-84,436,030-78,609,787
Stockholders’ equity:Total stockholders’ equity3,767,5437,072,522
Stockholders’ equity:Total liabilities and stockholders’ equity6,186,09510,785,647
Full release

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward looking statements by the words or phrases “may,”

“might,” “will,” “could,” “would,” “should,” “expect,”

“intend,” “plan,” “forecasts,” “objective,” “anticipate,”

“believe,” “estimate,” “predict,” “project,” “potential,”

“target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward looking statements may include statements regarding the potential sales of the StereoCED

TM drug delivery platform in investigational clinical studies or animals in Q4 fiscal 2026, 2026 guidance, the collaborations with the

University of Minnesota and other companies, our ability to expand internationally, our ability to ship back-ordered product, our ability to expand the sales of our OneRF®

Trigeminal Nerve Ablation System, our and the Company’s ability to expand revenue. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology whether due to supply chain disruptions, labor shortages or otherwise risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology uncertainties inherent in the development process of our technology risks related to changes in regulatory requirements or decisions of regulatory authorities that we may not have accurately estimated the size and growth potential of the markets for our technology risks related to clinical trial patient enrollment and the results of clinical trials that we may be unable to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission.

These forward looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward looking statements for any reason, even if new information becomes available in the future.

Caution:

Federal law restricts this device to sale by or on the order of a physician.

IR

Contact

MZ

Group – MZ North America

NMTC@mzgroup.us

NeuroOne

Medical Technologies Corporation

Condensed

Balance Sheets

NeuroOne

Medical Technologies Corporation

Condensed

Statements of Operations

(unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · NEUROONE MEDICAL TECHNOLOGIES earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.